Why the study?
Improved survival with systemic therapies has heightened the importance of melanoma survivorship, as cancer and its treatments are associated with increased cardiovascular morbidity and mortality.
Melanoma survivorship requires attention to cardiovascular risk modification due to the cardiotoxic effects of systemic therapies like immune checkpoint inhibitors and BRAF-MEK inhibitors.
Cardiovascular risk modification is now warranted in melanoma survivors on ICI or BRAF-MEK therapy; confirms mixed cardiotoxicity signals and leaves prevention trials open.
In the last decade, systemic therapies such as immune checkpoint inhibitors and BRAF-MEK inhibitors have improved the prognosis of high-risk and advanced melanoma. With improved survival, melanoma survivorship is increasingly important, particularly in patients who have a good prognosis or are diagnosed at a younger age. It is increasingly recognized that cancer and its treatment is associated with increased cardiovascular morbidity and mortality. Indeed, data from observational studies and meta-analyses of randomized controls trials in melanoma show that systemic therapies may be associated with cardiac toxicities, such as myocardial infarction, heart failure, myocarditis and stroke. Our review will discuss cardiovascular disease and risk factors in the context of melanoma and outline the importance of cardiovascular risk modification in this population.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: